Skip to main content
    R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $162.78
    -5.01 (-2.99%)

    Market Cap: $10.73B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Repligen Corporation (RGEN) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Repligen reported revenue of $738.26M for the fiscal year ended Dec 31, 2025, up 16.4% from the year before. That year, net income was $48.89M with a net margin of 6.6%, operating cash flow was $117.42M and free cash flow was $93.90M. The quarter ended Sep 30, 2026 had revenue of $209.31M and net income of -$38.43M.

    Revenue and Margins

    The operating margin was 7.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $208.98M, a compound annual rate of 15.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$738.26M+16.4%52.3%7.5%6.6%
    Dec 2024$634.44M+0.3%43.3%-5.5%-4.0%
    Dec 2023$632.36M-21.1%44.0%7.5%5.6%
    Dec 2022$801.54M+19.5%56.9%28.0%23.2%
    Dec 2021$670.53M+83.1%58.3%24.9%19.1%
    Dec 2020$366.26M+35.5%57.2%19.1%16.4%
    Dec 2019$270.25M+39.3%55.9%13.4%7.9%
    Dec 2018$194.03M+37.4%55.4%13.4%8.6%
    Dec 2017$141.24M-32.4%52.5%9.9%20.1%
    Dec 2016$208.98MN/A77.5%7.6%5.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$738.26M$634.44M$632.36M$801.54M$670.53M$366.26M$270.25M$194.03M$141.24M$208.98M
    Cost of revenue$352.01M$359.79M$353.92M$345.83M$279.28M$156.63M$119.10M$86.53M$67.05M$47.12M
    Gross profit$386.25M$274.64M$278.44M$455.71M$391.25M$209.63M$151.15M$107.50M$74.19M$161.87M
    Research and development$54.18M$43.20M$42.72M$43.94M$34.27M$20.18M$19.45M$15.82M$8.67M$7.36M
    Operating income$55.17M-$35.11M$47.70M$224.67M$167.25M$69.82M$36.08M$25.99M$14.01M$15.97M
    Net income$48.89M-$25.51M$35.60M$185.96M$128.29M$59.93M$21.41M$16.62M$28.35M$11.68M
    EBITDA$151.71M$43.13M$118.75M$266.12M$225.18M$106.28M$64.17M$46.28M$27.80M$22.72M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$209.31M$204.13M$194.25M$197.91M$188.81M$182.37M$169.17M$167.55M$154.87M$158.84M$153.18M$166.62M
    Gross profit$110.99M$110.04M$108.28M$103.83M$100.52M$93.00M$91.37M$38.84M$77.49M$81.53M$76.79M$78.48M
    Operating income-$29.55M$13.98M$15.94M$17.87M$16.82M$13.90M$6.58M-$36.50M-$7.83M$5.47M$3.75M$9.87M
    Net income-$38.43M$5.01M$8.33M$13.29M$14.91M$14.87M$5.83M-$33.87M-$654.00K$5.71M$3.30M-$16.45M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $547.26M by $18.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$2.95B$2.83B$2.83B$2.53B$2.36B$1.90B$1.40B$774.62M$743.52M$288.91M
    Current assets$1.14B$1.07B$1.11B$998.12M$931.68M$902.38M$641.83M$275.74M$242.78M$184.15M
    Cash and equivalents$566.02M$757.36M$751.32M$523.46M$603.81M$717.29M$528.39M$193.82M$173.76M$122.23M
    Total liabilities$843.57M$856.95M$866.34M$620.90M$608.29M$373.74M$340.35M$159.05M$151.97M$120.15M
    Short-term debt$5.05M$17.13M$82.44M$298.56M$255.26M$243.74M$0$103.49M$0$95.27M
    Long-term debt$542.21M$525.57M$510.14M$0N/AN/A$232.77MN/A$99.25M$95.27M
    Shareholder equity$2.11B$1.97B$1.96B$1.91B$1.75B$1.53B$1.06B$615.57M$591.55M$168.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.93B$2.95B$2.93B$2.95B$2.92B$2.90B$2.85B$2.83B$2.83B$2.87B$2.85B$2.83B
    Total liabilities$834.67M$838.15M$825.31M$843.57M$840.62M$839.89M$866.66M$856.95M$813.96M$881.57M$888.10M$866.34M
    Cash and equivalents$726.96M$606.78M$582.65M$566.02M$748.75M$708.86M$697.23M$757.36M$783.96M$809.15M$780.62M$751.32M
    Shareholder equity$2.09B$2.11B$2.11B$2.11B$2.08B$2.06B$1.99B$1.97B$2.02B$1.98B$1.97B$1.96B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 80.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$117.42M$175.39M$113.92M$172.08M$119.02M$62.63M$67.22M$32.77M$17.45M$7.52M
    Capital expenditures$23.52M$25.68M$36.22M$84.83M$67.09M$22.45M$18.50M$11.89M$5.45M$4.33M
    Free cash flow$93.90M$149.72M$77.70M$87.25M$51.93M$40.17M$48.71M$20.88M$12.00M$3.20M
    Dividends paidN/AN/A$565.68M$17.02M$2.90MN/A$490.00KN/A$0$798.00K
    Share repurchases$0$0$14.39M$0$0N/AN/AN/AN/AN/A
    Investing cash flow-$298.47M-$86.38M-$123.28M-$233.24M-$221.17M-$201.38M-$205.31M-$14.04M-$98.70M-$49.19M
    Financing cash flow-$15.21M-$82.90M$248.96M-$13.34M$961.00K$305.92M$484.87M$3.41M$129.94M$112.11M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$43.10M$32.77M$28.30M$25.70M$48.10M$28.61M$15.01M$39.18M$49.32M$42.19M$44.71M$29.07M
    Capital expenditures$4.95M$5.33M$4.71M$8.15M$4.70M$7.10M$3.56M$5.54M$6.98M$4.81M$8.35M$11.09M
    Free cash flow$38.15M$27.43M$23.59M$17.55M$43.40M$21.51M$11.44M$33.64M$42.34M$37.38M$36.36M$17.98M
    Last 12 quarters

    Frequently Asked Questions About RGEN

    What is Repligen's annual revenue?

    Repligen reported revenue of $738.26M for the fiscal year ended Dec 31, 2025.

    How fast is Repligen's revenue growing?

    Revenue was up 16.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.7%.

    Is Repligen profitable?

    Yes. Repligen reported net income of $48.89M for the fiscal year ended Dec 31, 2025, with a net margin of 6.6%.

    How much free cash flow does RGEN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $117.42M minus capital expenditures of $23.52M produced free cash flow of $93.90M.

    How much debt does Repligen have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $542.21M, short-term debt of $5.05M and cash and equivalents of $566.02M.